Such studies could enable broader implementation of circulating miRNA biomarkers of β-cell dysfunction in combination with other relevant biomarker types (e. g., glucose/insulin levels, cytokine and/or autoantibody levels) for stratifying patients at an early stage – before clinical diabetes develops, predicting the progression of disease, guiding therapy, and/or monitoring responses to targeted interventions. Here, INS is linked to diabetes mellitus.